NCT05754710View on ClinicalTrials.gov

Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis

RecruitingOBSERVATIONAL

Enrollment

375

Participants

Timeline

Start Date

April 12, 2024

Primary Completion Date

January 24, 2027

Study Completion Date

January 24, 2027

Conditions

Psoriatic Arthritis, JuvenilePolyarticular Juvenile Idiopathic Arthritis

Interventions

DRUG

Xeljanz

Juvenile Idiopathic Arthritis (JIA) patients with Xeljanz

Trial Locations (1)

Unknown

RECRUITING

Pfizer, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY

NCT05754710 - Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis | Biotech Hunter | Biotech Hunter